Unique Properties of Coactivator Recruitment Caused by Differential Binding of FK614, an Anti-diabetic Agent, to Peroxisome Proliferator-Activated Receptor γ(Molecular and Cell Biology)
スポンサーリンク
概要
- 論文の詳細を見る
FK614 is a structurally novel class of peroxisome proliferator-activated receptor γ (PPARγ) agonist, with the mechanism of its insulin-sensitizing action most likely due to activation of PPARγ. In this study, properties of FK614 for PPARγ binding, ability to induce conformational change, and coactivator recruitment were investigated. FK614, rosiglitazone, and pioglitazone competed specific binding of [^3H]rosiglitazone to PPARγ with K_i values of 11 nM, 47 nM, and 1.3μM, respectively. Limited trypsin digestion of PPARγ with FK614 or rosiglitazone produced distinct patterns of digested polypeptides, suggesting that FK614 directly binds to PPARγ but induces specific alterations in receptor conformation. FK614 induced interaction of PPARγ with nuclear receptor coactivator CBP but of lower magnitude than rosiglitazone and pioglitazone. The estimated K_d values of FK614-, rosiglitazone-, and pioglitazone-PPARγ complex to CBP peptide were 1.8, 0.64, and 0.72μM, respectively, indicating FK614-PPARγ complex exhibits a lower affinity for CBP peptide compared to other agonist-PPARγ complexes. When tested the effect of FK614 on CBP recruitment induced by 9(S)-hydroxyoctadecadienoic acid, an endogenous ligand, FK614 negatively modulated PPARγ activation. The unique properties of FK614 may underlie the molecular basis of ligand-dependent transcriptional modulation mediated by PPARγ.
- 社団法人日本薬学会の論文
- 2006-03-01
著者
-
FUJIMURA TAKAO
Pharmacological Research Laboratories, Fujisawa Pharmaceutical Co. Ltd.
-
FUJIMURA Takao
Molecular Medicine Research Laboratories, Astellas Pharma Inc.
-
ARAMORI Ichiro
Molecular Medicine Research Laboratories, Astellas Pharma Inc.
-
MUTOH Seitaro
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
Mutoh Seitaro
Pharmacology Res. Labs Astellas Pharma Inc. Jpn
-
Aramori Ichiro
Molecular Medicine Research Laboratories Astellas Pharma Inc.
-
Fujimura Takao
Molecular Medicine Research Laboratories Astellas Pharma Inc.
-
Fujimura Takao
Pharmacological Research Laboratories Fujisawa Pharmaceutical Co. Ltd.
-
SAKUMA Hiroyuki
Pharmacology Research Laboratories, Astellas Pharma Inc.
-
OHKUBO-SUZUKI Akiko
Molecular Medicine Research Laboratories, Astellas Pharma Inc.
-
Sakuma Hiroyuki
Pharmacology Research Laboratories Astellas Pharma Inc.
-
Ohkubo-suzuki Akiko
Molecular Medicine Research Laboratories Astellas Pharma Inc.
関連論文
- An Approach to High-Level Production of Cephalosporin Acylase from Pseudomonas strain N176 in Escherichia coli
- Novel Method for Selecting Immunosuppressive Histone Deacetylase (HDAC) Inhibitors with Minimal Thrombocytopenia(Molecular and Cell Biology)
- Tacrolimus (FK506) Limits Accumulation of Granulocytes and Platelets and Protects against Brain Damage after Transient Focal Cerebral Ischemia in Rat(Pharmacology)
- Evaluation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtype Selectivity of a Variety of Anti-inflammatory Drugs Based on a Novel Assay for PPARδ(β)
- Unique Properties of Coactivator Recruitment Caused by Differential Binding of FK614, an Anti-diabetic Agent, to Peroxisome Proliferator-Activated Receptor γ(Molecular and Cell Biology)
- FK614, a Novel Peroxisome Proliferator-Activated Receptor γ Modulator, Induces Differential Transactivation Through a Unique Ligand-Specific Interaction With Transcriptional Coactivators
- Efficacy of Oral Treatment With Tacrolimus in the Renal Transplant Model in Cynomolgus Monkeys
- Effect of a New Immunosuppressant Histon Deacetylase (HDAC) Inhibitor FR276457 in a Rat Cardiac Transplant Model(Pharmacology)
- Direct Comparison of the Pharmacodynamics of Four Antifungal Drugs in a Mouse Model of Disseminated Candidiasis Using Microbiological Assays of Serum Drug Concentrations
- Determination of Antifungal Activities in Serum Samples from Mice Treated with Different Antifungal Drugs Allows Detection of an Active Metabolite of Itraconazole
- Chemical Modification and Site-Directed Mutagenesis of Tyrosine Residues in Cephalosporin C Acylase from Pseudomonas Strain N176
- A Novel 7-β-(4-Carboxybutanamido)-Cephalosporanic Acid Acylase Isolated from Pseudomonas Strain C427 and Its High-Level Production in Escherichia coli
- Large Scale Purification of Recombinant Insulin-Like Growth Factor I (IGF-I, Mecasermin) from a Fused Protein Produced in Escherichia coli
- Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds
- Pharmacological Properties of FK886, a New, Centrally Active Neurokinin-1 Receptor Antagonist